By Glen S. Woods : The giant Swiss multinational healthcare company Novartis ( NVS ) has seen its stock rise almost 25% YTD, and while it will lose revenue due to patent expiration on three of its most profitable drugs, including Glivec, Zometa and Diovan - new drugs working through the pipeline ...
By Sharon di Stefano : Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks. Keeping its promise to give men better alternatives to stem hair loss and restore vitality, DS Healthcare Group, Inc. ( DSKX ) announced a new tablet for baldness
GE) is the biggest; in consumer discretionary, Amazon (AMZN) takes the lead; and in health care, it’s Johnson & Johnson ( JNJ ). On a year-to-date basis, in industrials, airlines such as Delta (DAL), have taken off. Among discretionary
BRUSSELS, Dec 10 (Reuters) - European Union regulators have fined drugmakers Johnson & Johnson and Novartis 16.3 million euros ($22 million) for blocking the sale of a cheaper generic rival to their...
BRUSSELS, Dec 10 (Reuters) - European Union antitrust regulators fined drugmakers Johnson & Johnson and Novartis a total of 16 million euros ($21.95 million) on Tuesday for blocking the sale of a generic painkiller in the Dutch market.
Dec 8 (Reuters) - A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow
implants, such as knees and hips. Both of these markets are roughly 75% controlled by three major players - Johnson & Johnson ( JNJ ), Stryker and Zimmer ( ZMH ) - with each holding roughly equal shares. Long-term growth prospects driven
biotech company Genmab said on Friday: * To receive milestone payment of $4 million from Janssen Biotech, a part of Johnson & Johnson * Revises 2013 financial guidance upwards * Now sees operating result of continuing operations in the range of positive
caused by its vaginal mesh products. The issue is not unique to Endo--competitors CR Bard, Boston Scientific, Johnson & Johnson , and others are facing litigation for similar products--but it could face a significant financial liability
begun using it. Insulet's main danger comes from well-financed competitors like Medtronic, Abbott, Roche, and Johnson & Johnson , which already possess large salesforces and relationships with medical professionals. Medtronic is developing